---
title: "Why Is Athira Pharma Stock (ATHA) Up Today?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270162675.md"
description: "Athira Pharma (ATHA) stock surged 63.97% in pre-market trading after announcing an agreement to acquire global rights (excluding certain Asian countries) for lasofoxifene, a potential metastatic breast cancer treatment, from Sermonix Pharmaceuticals. The deal includes a pre-funded warrant for 5.5 million ATHA shares and up to $100 million in milestone payments. Athira also announced a $90 million private placement, potentially raising an additional $146 million if warrants are exercised. Despite recent gains, ATHA stock is down 29.56% year-to-date."
datetime: "2025-12-18T12:59:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270162675.md)
  - [en](https://longbridge.com/en/news/270162675.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270162675.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/270162675.md) | [繁體中文](https://longbridge.com/zh-HK/news/270162675.md)


# Why Is Athira Pharma Stock (ATHA) Up Today?

Athira Pharma (ATHA) stock rocketed higher on Thursday after the late clinical-stage biopharmaceutical company announced an agreement to acquire the rights for the development and commercialization of lasofoxifene. Lasofoxifene is a selective estrogen receptor modulator (SERM) for the potential treatment of metastatic breast cancer. It's currently in a Phase 3 trial with data expected in 2027.

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

Athira Pharma's deal has seen it acquire an exclusive global license to lasofoxifene, excluding certain Asian countries, from Sermonix Pharmaceuticals. The agreement granted Sermonix Pharmaceuticals a pre-funded warrant to acquire 5.5 million shares of ATHA stock. Athira Pharma has also agreed to pay Sermonix Pharmaceuticals up to $100 million if certain milestones for lasofoxifene's are reached, including royalties on net sales.

To go along with this news, Athira Pharma revealed a $90 million private placement. This includes a mix of shares and warrants. If the warrants are exercised, the company could receive an additional $146 million in funding. These funds will be used to support the lasofoxifene development program.

## **Athira Pharma Stock Movement Today**

Athira Pharma stock was up 63.97% in pre-market trading on Thursday, following a 6.57% rally yesterday. However, the stock has fallen 29.56% year-to-date and 24.53% over the past 12 months.

With today's news came heavy trading of ATHA stock, as more than 8 million shares changed hands, compared to a three-month daily average trading volume of about 41,000 units.

## Related News & Research

- [India govt official: domestic production of urea has been affected due to Iran war](https://longbridge.com/en/news/280992705.md)
- [India govt official: urea units operating at 80% capacity](https://longbridge.com/en/news/280992730.md)
- [06:00 ETPostpartum Care Conversations Shift Toward Practical Support and Simplified Self-Care for New Mothers](https://longbridge.com/en/news/280995362.md)
- [EOS Wins New U.S. Weapon Systems Deals and Advances Korean Laser Contract](https://longbridge.com/en/news/281098133.md)
- [Nuclera Launches GPCR-Focused Nanodisc Panel to Streamline Membrane Protein Production](https://longbridge.com/en/news/280981414.md)